# MSA Safety Inc: overview

MSA · NYSE · CIK 66570 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/msa.md) · [Financials](/companies/msa/financials.md) · [Filings](/companies/msa/filings.md) · [Insiders](/companies/msa/insiders.md)

Latest reported revenue: [$503.3m](/filings/0000066570-26-000027.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000066570-26-000027).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [433](/filings/0000066570-26-000005.md) | [500](/filings/0000066570-26-000005.md) | [421](/filings/0000066570-26-000012.md) | [474](/filings/0000066570-26-000027.md) | [468](/filings/0000066570-26-000005.md) | [511](/filings/0000066570-26-000005.md) | [464](/filings/0000066570-26-000012.md) | [503](/filings/0000066570-26-000027.md) |
| Gross margin | % | [47.9%](/filings/0000066570-26-000005.md) | [46.9%](/filings/0000066570-26-000005.md) | [45.9%](/filings/0000066570-26-000012.md) | [46.6%](/filings/0000066570-26-000027.md) | [46.5%](/filings/0000066570-26-000005.md) | [46.9%](/filings/0000066570-26-000005.md) | [47.4%](/filings/0000066570-26-000012.md) | [49.5%](/filings/0000066570-26-000027.md) |
| Operating margin | % | [21.1%](/filings/0000066570-25-000042.md) | [23.5% d](/filings/0000066570-26-000005.md) | [18.5%](/filings/0000066570-26-000012.md) | [18.1%](/filings/0000066570-26-000027.md) | [20.1%](/filings/0000066570-25-000042.md) | [22.3% d](/filings/0000066570-26-000005.md) | [20.1%](/filings/0000066570-26-000012.md) | [22.2%](/filings/0000066570-26-000027.md) |
| Net margin | % | [15.4%](/filings/0000066570-26-000005.md) | [17.6%](/filings/0000066570-26-000005.md) | [14.1%](/filings/0000066570-26-000012.md) | [13.2%](/filings/0000066570-26-000027.md) | [14.9%](/filings/0000066570-26-000005.md) | [17.0%](/filings/0000066570-26-000005.md) | [15.4%](/filings/0000066570-26-000012.md) | [17.1%](/filings/0000066570-26-000027.md) |
| Diluted EPS | $ per share | [1.69](/filings/0000066570-26-000005.md) | [2.22](/filings/0000066570-26-000005.md) | [1.51](/filings/0000066570-26-000012.md) | [1.59](/filings/0000066570-26-000027.md) | [1.77](/filings/0000066570-26-000005.md) | [2.21](/filings/0000066570-26-000005.md) | [1.83](/filings/0000066570-26-000012.md) | [2.23](/filings/0000066570-26-000027.md) |
| Free cash flow | $m | [70.1 d](/filings/0000066570-25-000042.md) | [93.5 d](/filings/0000066570-26-000005.md) | [51.0](/filings/0000066570-26-000012.md) | [37.9 d](/filings/0000066570-26-000027.md) | [100 d](/filings/0000066570-25-000042.md) | [106 d](/filings/0000066570-26-000005.md) | [65.1](/filings/0000066570-26-000012.md) | [82.7 d](/filings/0000066570-26-000027.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,400](/filings/0000066570-24-000008.md) | [1,528](/filings/0000066570-25-000007.md) | [1,788](/filings/0000066570-26-000005.md) | [1,808](/filings/0000066570-26-000005.md) | [1,875](/filings/0000066570-26-000005.md) |
| Gross margin | % | [43.9%](/filings/0000066570-24-000008.md) | [44.1%](/filings/0000066570-25-000007.md) | [47.7%](/filings/0000066570-26-000005.md) | [47.6%](/filings/0000066570-26-000005.md) | [46.5%](/filings/0000066570-26-000005.md) |
| Operating margin | % | [1.6%](/filings/0000066570-24-000008.md) | [15.7%](/filings/0000066570-25-000007.md) | [12.9%](/filings/0000066570-26-000005.md) | [21.5%](/filings/0000066570-26-000005.md) | [19.8%](/filings/0000066570-26-000005.md) |
| Net margin | % | [1.5%](/filings/0000066570-24-000008.md) | [11.8%](/filings/0000066570-25-000007.md) | [3.3%](/filings/0000066570-26-000005.md) | [15.8%](/filings/0000066570-26-000005.md) | [14.9%](/filings/0000066570-26-000005.md) |
| Diluted EPS | $ per share | [0.54](/filings/0000066570-24-000008.md) | [4.56](/filings/0000066570-25-000007.md) | [1.48](/filings/0000066570-26-000005.md) | [7.21](/filings/0000066570-26-000005.md) | [7.09](/filings/0000066570-26-000005.md) |
| Free cash flow | $m | [155](/filings/0000066570-24-000008.md) | [115](/filings/0000066570-25-000007.md) | [50.1](/filings/0000066570-26-000005.md) | [242](/filings/0000066570-26-000005.md) | [295](/filings/0000066570-26-000005.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/msa/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $581.7m | 3,331,741 |  | Added +80,024 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $319.3m | 1,828,682 |  | Reduced −13,581 |
| [Ruane, Cunniff & Goldfarb L.P.](/funds/1720792.md) | 2026-06-30 | $300.5m | 1,721,415 |  | Reduced −54,867 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $298.3m | 1,708,900 |  | Added +5,117 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $283.8m | 1,626,476 |  | Added +87,786 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $137.4m | 796,788 |  | Added +37,096 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $135.1m | 773,699 |  | Added +15,355 |
| [COOKE & BIELER LP](/funds/24386.md) | 2026-06-30 | $126.6m | 725,229 |  | Reduced −120,259 |
| [FIDUCIARY MANAGEMENT INC /WI/](/funds/764532.md) | 2026-06-30 | $124.6m | 713,768 |  | Added +34,782 |
| [M&G PLC](/funds/1802539.md) | 2026-06-30 | $120.8m | 690,334 |  | Reduced −7,668 |

## Recent filings

[All 1,539 filings](/companies/msa/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-31 | 16:33 ET | [10-Q](/filings/0000066570-26-000027.md) | Quarterly report, period 2026-06-30 | 0000066570-26-000027 |
| 2026-07-30 | 16:35 ET | [8-K](/filings/0000066570-26-000025.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000066570-26-000025 |
| 2026-07-21 | 16:34 ET | [8-K](/filings/0000066570-26-000022.md) | 5.02 Departure or appointment of officers or directors | 0000066570-26-000022 |
| 2026-07-09 | 16:53 ET | [8-K](/filings/0000066570-26-000019.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000066570-26-000019 |
| 2026-05-08 | 16:03 ET | [8-K](/filings/0000066570-26-000014.md) | 5.07 Shareholder vote results | 0000066570-26-000014 |
| 2026-05-05 | 16:30 ET | [10-Q](/filings/0000066570-26-000012.md) | Quarterly report, period 2026-03-31 | 0000066570-26-000012 |
| 2026-05-05 | 08:45 ET | [8-K](/filings/0001140361-26-019007.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-019007 |
| 2026-05-04 | 16:35 ET | [8-K](/filings/0000066570-26-000010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000066570-26-000010 |
| 2026-03-26 | 14:05 ET | [DEF 14A](/filings/0001193125-26-125902.md) | Proxy statement, period 2026-05-08 | 0001193125-26-125902 |
| 2026-02-26 | 08:31 ET | [8-K](/filings/0000066570-26-000007.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000066570-26-000007 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000066570-26-000005.md), filed Feb 12, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/715c733d-b551-47cb-ae63-e6bbb637e877)

## About the filer

- CIK: 66570
- Tickers: MSA, MNESP
- Exchange: NYSE
- SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.